VC-backed start-ups may need to think and act differently, perhaps more judiciously, about effective governance than more established firms. The stakes for start-ups are higher and the environment for failure is less forgiving than for established enterprises. In addition to their oversight role, directors at start-ups should be considered strategic assets. Developing a relation-based model built on a board/CEO partnership can increase the odds for success.
By Joe Mandato
In an interview in Fortune last summer, Intel Corp. chairman Andy Grove explained how he had shifted the primary mission...
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
Recent moves in the industry include changes at the top at Trogenix and Quetzal Therapeutics, plus Synendos Therapeutics gains a new CMO from Roche.
The Danish medical dermatology specialist doubles boosts its sales force ahead of the launch of Anzupgo.
Stock shoots up over 460% on positive results in two ulcerative colitis trials of the oral first-in-class candidate.
A deal last year with Sanofi relieved Novavax of commercial costs for the COVID-19 vaccine Nuvaxovid, allowing the company to focus on R&D and finding partners for its other vaccines.
Recent moves in the industry include changes at the top at Trogenix and Quetzal Therapeutics, plus Synendos Therapeutics gains a new CMO from Roche.
Pointing to data that show a benefit in reducing viral load and the histological signs of the infection, Memo says its drug, potravitug, could become the first therapy to treat BK polyomavirus in kidney transplant recipients.
In its Q2 update, Viking reported that Phase III trials of subcutaneous VK2735 are under way, and that it expects Phase II data for an oral formulation before year’s end.
